These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 32531439)

  • 1. Response to Kawedia et al Letter to Editor in Response to the Article by McCune Et Al "Harmonization of Busulfan Plasma Exposure Unit (BPEU): A Community-Initiated Consensus Statement".
    Dupuis LL; Quinones CM; Ritchie J; Carpenter PA; Bauters T; Yeh RF; Anasetti C; Boelens JJ; Hamerschlak N; Hassan M; Kang HJ; Kanda Y; Paci A; Perales MA; Shaw PJ; Seewaldt VL; Savani BN; Militano O; Pulsipher MA; McCune JS
    Biol Blood Marrow Transplant; 2020 Sep; 26(9):e235-e236. PubMed ID: 32531439
    [No Abstract]   [Full Text] [Related]  

  • 2. Letter to the Editor Regarding "Harmonization of Busulfan Plasma Exposure Unit (BPEU): A Community-Initiated Consensus Statement".
    Kawedia JD; Handy VW; Shigle TL; Gulbis AM; Nieto Y; Andersson BS
    Biol Blood Marrow Transplant; 2020 Sep; 26(9):e232-e234. PubMed ID: 32407883
    [No Abstract]   [Full Text] [Related]  

  • 3. Harmonization of Busulfan Plasma Exposure Unit (BPEU): A Community-Initiated Consensus Statement.
    McCune JS; Quinones CM; Ritchie J; Carpenter PA; van Maarseveen E; Yeh RF; Anasetti C; Boelens JJ; Hamerschlak N; Hassan M; Kang HJ; Kanda Y; Paci A; Perales MA; Shaw PJ; Seewaldt VL; Savani BN; Hsieh A; Poon B; Mohty M; Pulsipher MA; Pasquini M; Dupuis LL
    Biol Blood Marrow Transplant; 2019 Sep; 25(9):1890-1897. PubMed ID: 31136799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of existing limited sampling models for busulfan kinetics in children with beta thalassaemia major undergoing bone marrow transplantation.
    Balasubramanian P; Chandy M; Krishnamoorthy R; Srivastava A
    Bone Marrow Transplant; 2001 Nov; 28(9):821-5. PubMed ID: 11781641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response to letter to the editor regarding Alqahtani et al. Article on priority review drugs approved by the FDA and the EMA: time for international regulatory harmonization of pharmaceuticals?
    Seoane-Vazquez E; Rodriguez-Monguio R; Alqahtani S
    Pharmacoepidemiol Drug Saf; 2016 Jun; 25(6):745-6. PubMed ID: 27245860
    [No Abstract]   [Full Text] [Related]  

  • 6. Response to the letter to the Editor regarding Zeukeng et al.'s article A comparison of new drugs approved by the FDA, the EMA, and Swissmedic: an assessment of the international harmonization of drugs.
    Zeukeng MJ; Seoane-Vazquez E; Bonnabry P
    Eur J Clin Pharmacol; 2018 Sep; 74(9):1199-1200. PubMed ID: 29802425
    [No Abstract]   [Full Text] [Related]  

  • 7. Letter by Spartalis et al Regarding Article, "Cardiomyocyte Regeneration: A Consensus Statement".
    Spartalis M; Tzatzaki E; Spartalis E
    Circulation; 2018 Mar; 137(10):1094-1095. PubMed ID: 29507004
    [No Abstract]   [Full Text] [Related]  

  • 8. [Successful treatment of primary myelofibrosis by busulfan pulse therapy: report of a case].
    Uemura Y; Iwahara Y; Kataoka R; Muneishi H; Miyoshi I
    Rinsho Ketsueki; 1990 Sep; 31(9):1553-6. PubMed ID: 2246832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantification of busulfan in saliva and plasma in haematopoietic stem cell transplantation in children : validation of liquid chromatography tandem mass spectrometry method.
    Rauh M; Stachel D; Kuhlen M; Gröschl M; Holter W; Rascher W
    Clin Pharmacokinet; 2006; 45(3):305-16. PubMed ID: 16509762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gas-chromatographic analysis of busulfan for therapeutic drug monitoring.
    Embree L; Burns RB; Heggie JR; Phillips GL; Reece DE; Spinelli JJ; Hartley DO; Hudon NJ; Goldie JH
    Cancer Chemother Pharmacol; 1993; 32(2):137-42. PubMed ID: 8485808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Binding of busulfan to plasma proteins and blood cells.
    Ehrsson H; Hassan M
    J Pharm Pharmacol; 1984 Oct; 36(10):694-6. PubMed ID: 6150090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A limited sampling strategy for pharmacokinetic directed therapy with intravenous busulfan.
    Vaughan WP; Carey D; Perry S; Westfall AO; Salzman DE
    Biol Blood Marrow Transplant; 2002; 8(11):619-24. PubMed ID: 12463481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determination of busulfan in human plasma using high-performance liquid chromatography with pre-column derivatization and fluorescence detection.
    Peris JE; Latorre JA; Castel V; Verdeguer A; Esteve S; Torres-Molina F
    J Chromatogr B Biomed Sci Appl; 1999 Jun; 730(1):33-40. PubMed ID: 10437669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic and metabolic studies of busulfan in rat plasma and brain.
    Hassan M; Ehrsson H; Wallin I; Eksborg S
    Eur J Drug Metab Pharmacokinet; 1988; 13(4):301-5. PubMed ID: 3243326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of a high-performance liquid chromatographic assay method for pharmacokinetic evaluation of busulfan.
    Heggie JR; Wu M; Burns RB; Ng CS; Fung HC; Knight G; Barnett MJ; Spinelli JJ; Embree L
    J Chromatogr B Biomed Sci Appl; 1997 May; 692(2):437-44. PubMed ID: 9188834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response to the Letter to the Editor From Marcotte (2019) Regarding "The History of Stuttering by 7 Years: Follow-Up of a Prospective Community Cohort" by Kefalianos et al. (2017).
    Kefalianos E; Onslow M; Packman A; Vogel A; Pezic A; Mensah F; Conway L; Bavin E; Block S; Reilly S
    J Speech Lang Hear Res; 2019 May; 62(5):1369-1370. PubMed ID: 31058567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship of plasma pharmacokinetics of high-dose oral busulfan to the outcome of allogeneic bone marrow transplantation in children with thalassemia.
    Pawlowska AB; Blazar BR; Angelucci E; Baronciani D; Shu XO; Bostrom B
    Bone Marrow Transplant; 1997 Dec; 20(11):915-20. PubMed ID: 9422469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Scientific basis of the OCRA method for risk assessment of biomechanical overload of upper limb, as preferred method in ISO standards on biomechanical risk factors.
    Colombini D; Occhipinti E
    Scand J Work Environ Health; 2018 Jul; 44(4):436-438. PubMed ID: 29961081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determination of busulfan in human plasma using an ELISA format.
    Courtney JB; Harney R; Li Y; Lundell G; McMillin GA; Agarwal G; Juenke JM; Mathew A; Gonzalez-Espinoza R; Fleisher M; Salamone SJ
    Ther Drug Monit; 2009 Aug; 31(4):489-94. PubMed ID: 19494794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determination of busulfan in human plasma by gas chromatography with electron-capture detection.
    Chen TL; Grochow LB; Hurowitz LA; Brundrett RB
    J Chromatogr; 1988 Mar; 425(2):303-9. PubMed ID: 3372644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.